Brian Skorney

ThinkEquity LLC analyst Brian Skorney maintained his Hold rating for shares of Vertex Pharmaceuticals Inc. (Nasdaq: VRTX). Skorney wrote that he maintained his Hold rating for Vertex Pharmaceuticals Inc. because he thought that shares of the biotechnology company were fairly valued. Although...

Think Equity is maintaining a Hold on Cubist (NASDAQ: CBST) on a report that the pharmaceutical company has terminated development of CB-500,929 aka ecallantide. An analyst at Think Equity weighed in on this decision in the following statement: “Following an announcement in December that the...

Analyst Brian Skorney at ThinkEquity LLC has released an update on SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN). BioAlliance Pharma s.a. received an approval to market ondansetron RapidFilm in 16 countries in the European Union. ThinkEquity believes that this news could give a lift to SciClone...

Analyst Brian Skorney of ThinkEquity Partners maintains his "hold" rating on Idenix Pharmaceuticals (NASDAQ: IDIX). The key driver of Idenix Pharmaceuticals’ shares is the company's proprietary nucleotide analog polymerase inhibitor, IDX184. IDIX has reported top-line results from the ongoing 14-...